An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects
Latest Information Update: 06 Dec 2022
At a glance
- Drugs CKD-388 (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
- 28 Dec 2020 New trial record